中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

血浆胆汁酸在肝肿瘤中的差异分析及应用价值

贾茹 张平平 袁苑 胡义扬 冯琴

戴维佳, 赖荣陶, 王晖, 谢青, 汤伟亮, 庄焱, 桂红莲, 余敏杰, 谢敬东, 周慧娟. 113例药物性肝损害临床特征及影响因素分析[J]. 临床肝胆病杂志, 2011, 27(10): 1058-1061+1065.
引用本文: 戴维佳, 赖荣陶, 王晖, 谢青, 汤伟亮, 庄焱, 桂红莲, 余敏杰, 谢敬东, 周慧娟. 113例药物性肝损害临床特征及影响因素分析[J]. 临床肝胆病杂志, 2011, 27(10): 1058-1061+1065.
Dai WeiJia, Lai RongTao, Wang Hui, Xie Qing, Tang WeiLiang, Zhuang Yan, Gui HongLian, Yu MinJie, Xie JingDong, Zhou HuiJuan. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J]. J Clin Hepatol, 2011, 27(10): 1058-1061+1065.
Citation: Dai WeiJia, Lai RongTao, Wang Hui, Xie Qing, Tang WeiLiang, Zhuang Yan, Gui HongLian, Yu MinJie, Xie JingDong, Zhou HuiJuan. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J]. J Clin Hepatol, 2011, 27(10): 1058-1061+1065.

血浆胆汁酸在肝肿瘤中的差异分析及应用价值

DOI: 10.12449/JCH241018
基金项目: 

国家自然科学基金 (82104619);

上海市卫健委卫生行业临床研究专项 (20214Y0455);

上海中医药大学预算内项目 (2021LK105)

伦理学声明:本研究方案经由上海中医药大学附属曙光医院伦理委员会审批,批号:2020-831-38-01。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:贾茹负责实验设计,样本采集,数据分析及论文撰写;张平平、袁苑负责样本采集及数据分析;胡义扬负责指导实验设计;冯琴负责指导实验设计及论文撰写并最终定稿。
详细信息
    通信作者:

    冯琴, fengqin@shutcm.edu.cn (ORCID: 0000-0002-4641-1636)

Differences and application value of plasma bile acids in tumors of the liver

Research funding: 

National Natural Science Foundation of China (82104619);

Shanghai Municipal Health Commission Health Industry Clinical Research Project (20214Y0455);

Project under Budget of Shanghai University of Traditional Chinese Medicine (2021LK105)

More Information
  • 摘要:   目的  分析原发性肝癌与转移性肝癌患者血浆胆汁酸水平及其与临床指标的相关性,并评估其联合AFP对于原发性肝癌的诊断价值。  方法  纳入2020年8月—2021年9月于上海中医药大学附属曙光医院就诊且具有组织病理学及影像学明确的75例原发性肝癌患者及79例转移性肝癌患者,采集外周血并分别分离血清及血浆,比色法及色谱法检测生化指标,电化学发光免疫分析法检测肿瘤标志物水平,高效液相色谱-串联质谱法检测胆汁酸含量。符合正态分布的计量资料两组间比较采用成组t检验,不符合正态分布的计量资料两组间比较采用Mann-Whitney U检验。相关性检验采用Spearman相关分析。临床诊断效能采用受试者工作特征曲线(ROC曲线)评估。  结果  原发性肝癌组患者TC、TG、LDL-C及载脂蛋白(Apo)B显著低于转移性肝癌组患者,差异均具有统计学意义(U值分别为1 598、1 255、909、889,P值均<0.05)。原发性肝癌组患者AFP显著高于转移性肝癌组患者,癌胚抗原(CEA)显著低于转移性肝癌组患者,差异均具有统计学意义(U值分别为1 873、926,P值均<0.05)。原发性肝癌组患者总胆汁酸(TBA)、胆酸(CA)、鹅脱氧胆酸(CDCA)、熊脱氧胆酸(UDCA)、牛磺胆酸(TCA)、牛磺鹅脱氧胆酸(TCDCA)、甘氨胆酸(GCA)、甘氨鹅脱氧胆酸(GCDCA)、牛磺熊脱氧胆酸(TUDCA)、甘氨熊脱氧胆酸(GUDCA)均显著高于转移性肝癌患者,脱氧胆酸(DCA)显著低于转移性肝癌患者,差异均具有统计学意义(P值均<0.05)。总人群中TBA、CDCA、GCA、GCDCA、GUDCA、TCA、TCDCA及TUDCA含量与AFP水平呈显著正相关(P值均<0.05)。原发性肝癌患者中GCA、TCA、TCDCA及TUDCA含量与AFP水平呈显著正相关(P值均<0.05)。AFP+TCA+GCA+TCDCA联合检测的AUC为0.822(95%CI:0.746~0.898,P<0.000 1),效能最高。  结论  原发性肝癌与转移性肝癌患者血浆胆汁酸含量具有显著差异,差异性胆汁酸与肝损伤及AFP升高密切相关,联合AFP对原发性肝癌具有更优的临床诊断价值。

     

  • 图  1  总人群中血浆胆汁酸含量与临床指标的相关性分析

    Figure  1.  Correlation analysis of plasma BA and clinical markers in all liver cancer patients

    图  2  原发性肝癌人群中血浆胆汁酸含量与临床指标的相关性分析

    Figure  2.  Correlation analysis of plasma BA and clinical markers in primary liver cancer patients

    图  3  AFP联合血浆胆汁酸区别原发性肝癌的ROC曲线分析

    Figure  3.  ROC curves of AFP combined with plasma BA for detection of primary liver cancer

    表  1  两组患者生化指标比较

    Table  1.   Comparison of levels of laboratory tests between patients with primary liver cancer or metastatic liver cancer

    项目 原发性肝癌组(n=75) 转移性肝癌组(n=79) 统计值 P
    ALT(U/L) 25.00(18.00~33.00) 22.00(12.00~37.00) U=2 375 0.177
    AST(U/L) 31.00(27.25~52.00) 29.00(20.75~46.00) U=1 933 0.063
    TBil(μmol/L) 20.10(13.70~30.90) 15.85(12.63~28.80) U=2 407 0.059
    GLU(mmol/L) 5.30(4.60~6.00) 5.05(4.70~6.00) U=2 636 0.925
    HbA1c(%) 5.40(4.90~6.00) 5.50(5.10~6.00) U=2 140 0.205
    TC(mmol/L) 3.87(3.31~4.58) 4.81(4.18~5.91) U=1 598 <0.001
    TG(mmol/L) 1.04(0.88~1.38) 1.31(1.07~1.85) U=1 255 <0.001
    HDL-C(mmol/L) 1.07±0.29 1.09±0.34 t=0.243 0.867
    LDL-C(mmol/L) 2.09(1.45~2.73) 3.06(2.38~4.08) U=909 <0.001
    ApoA1(g/L) 0.90(0.73~1.06) 0.93(0.81~1.14) U=1 474 0.154
    ApoB(g/L) 0.67(0.49~0.89) 0.93(0.69~1.16) U=889 <0.001
    下载: 导出CSV

    表  2  两组患者肿瘤标志物水平比较

    Table  2.   Comparison of levels of serum tumor markers between patients with primary liver cancer or metastatic liver cancer

    项目 原发性肝癌组(n=75) 转移性肝癌组(n=79) U P
    AFP(ng/mL) 6.45(3.16~15.74) 4.02(2.54~5.23) 1 873 <0.001
    CEA(ng/mL) 3.04(2.53~5.42) 15.14(5.02~83.18) 926 <0.001
    CA19-9(U/mL) 21.20(10.83~54.69) 21.36(10.22~154.38) 2 361 0.840
    CA125(U/mL) 18.70(12.50~36.20) 21.20(10.55~44.63) 1 181 0.128
    下载: 导出CSV

    表  3  两组患者血浆胆汁酸含量比较

    Table  3.   Comparison of concentrations of plasma BA between patients with primary liver cancer or metastatic liver cancer

    项目 原发性肝癌组(n=75) 转移性肝癌组(n=79) U P
    TBA(nmol/L) 11 675.7(6 098.5~33 679.9) 5 241.6(2 445.8~10 062.8) 886 <0.001
    CA(nmol/L) 290.7(148.6~1 030.0) 114.0(62.8~319.0) 1 084 <0.001
    CDCA(nmol/L) 2 570.0(766.4~3 040.0) 527.0(191.5~1 127.2) 750 <0.001
    DCA(nmol/L) 66.9(6.9~354.0) 238.3(19.1~572.0) 1 223 0.010
    UDCA(nmol/L) 199.0(109.5~572.5) 68.7(26.8~246.5) 1 039 <0.001
    LCA(nmol/L) 15.7(6.3~45.6) 21.2(10.7~39.9) 1 476 0.243
    TCA(nmol/L) 444.0(90.3~2 231.1) 47.2(11.3~482.2) 862 <0.001
    TCDCA(nmol/L) 627.0(256.0~5 060.0) 145.0(48.7~981.9) 828 <0.001
    GCA(nmol/L) 1 309.2(424.0~4 670.0) 444.6(190.5~1 400.4) 1 018 <0.001
    GCDCA(nmol/L) 3 530.0(1 160.0~13 341.0) 1 149.3(388.4~3 537.4) 978 <0.001
    TDCA(nmol/L) 23.6(0.0~114.0) 25.6(5.0~92.3) 1 423 0.144
    TUDCA(nmol/L) 41.8(10.8~117.0) 7.3(1.9~21.5) 832 <0.001
    TLCA(nmol/L) 0.9(0.2~4.0) 0.9(0.0~2.3) 1 520 0.352
    GDCA(nmol/L) 119.8(5.9~609.0) 187.0(13.7~498.0) 1 586 0.570
    GUDCA(nmol/L) 434.0(156.8~1 390.0) 104.0(49.9~637.1) 986 <0.001
    GLCA(nmol/L) 5.2(0.6~29.0) 6.4(1.8~19.8) 1 641 0.789
    下载: 导出CSV
  • [1] JIA W, XIE GX, JIA WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 2): 111- 128. DOI: 10.1038/nrgastro.2017.119.
    [2] CHÁVEZ-TALAVERA O, TAILLEUX A, LEFEBVRE P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 7): 1679- 1694.e3. DOI: 10.1053/j.gastro.2017.01.055.
    [3] SMIRNOVA E, MUTHIAH MD, NARAYAN N, et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD[J]. Hepatology, 2022, 76( 6): 1811- 1824. DOI: 10.1002/hep.32568.
    [4] CHEN T, WANG L, XIE G, et al. Serum bile acids improve prediction of Alzheimer's progression in a sex-dependent manner[J]. Adv Sci(Weinh), 2024, 11( 9): e2306576. DOI: 10.1002/advs.202306576.
    [5] SONG WS, PARK HM, HA JM, et al. Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma[J]. Sci Rep, 2018, 8( 1): 11088. DOI: 10.1038/s41598-018-29445-z.
    [6] JI SY, LIU QX, ZHANG SH, et al. FGF15 activates hippo signaling to suppress bile acid metabolism and liver tumorigenesis[J]. Dev Cell, 2019, 48( 4): 460- 474. e 9. DOI: 10.1016/j.devcel.2018.12.021.
    [7] SUN RQ, ZHANG ZY, BAO RX, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis[J]. J Hepatol, 2022, 77( 2): 453- 466. DOI: 10.1016/j.jhep.2022.02.030.
    [8] LIU ZR, JIA XD, LU YY. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. J Clin Hepatol, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038.

    刘哲睿, 贾晓东, 陆荫英. 肝细胞癌相关胆汁酸代谢失衡及调控机制的研究进展[J]. 临床肝胆病杂志, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038.
    [9] SYDOR S, BEST J, MESSERSCHMIDT I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC[J]. Clin Transl Gastroenterol, 2020, 11( 3): e00131. DOI: 10.14309/ctg.0000000000000131.
    [10] PETRICK JL, FLORIO AA, KOSHIOL J, et al. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies[J]. Int J Cancer, 2020, 147( 10): 2743- 2753. DOI: 10.1002/ijc.33051.
    [11] LI YY, LI JJ, SHI HF, et al. Advances in imaging research on source identification of primary liver metastases[J]. J Clin Radiol, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007.

    黎玉莹, 李晶晶, 石海峰, 等. 肝转移瘤原发灶来源鉴别的影像学研究进展[J]. 临床放射学杂志, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007.
    [12] JIA W, WEI ML, RAJANI C, et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases[J]. Protein Cell, 2021, 12( 5): 411- 425. DOI: 10.1007/s13238-020-00804-9.
    [13] LI TG, CHIANG JYL. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev, 2014, 66( 4): 948- 983. DOI: 10.1124/pr.113.008201.
    [14] WANG CZ, YANG MY, ZHAO JF, et al. Bile salt(glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234( 7): 10899- 10906. DOI: 10.1002/jcp.27905.
    [15] MA C, HAN MJ, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360( 6391): eaan5931. DOI: 10.1126/science.aan5931.
    [16] SARKAR J, AOKI H, WU RR, et al. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis[J]. Ann Surg Oncol, 2023, 30( 3): 1630- 1641. DOI: 10.1245/s10434-022-12806-4.
    [17] CHENG P, WU JW, ZONG GF, et al. Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver[J]. Pharmacol Res, 2023, 188: 106643. DOI: 10.1016/j.phrs.2022.106643.
    [18] HAN J, QIN WX, LI ZL, et al. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Clin Chim Acta, 2019, 488: 68- 75. DOI: 10.1016/j.cca.2018.10.039.
    [19] LUO P, YIN PY, HUA R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma[J]. Hepatology, 2018, 67( 2): 662- 675. DOI: 10.1002/hep.29561.
    [20] XIAN LF, FANG LT, LIU WB, et al. Epidemiological status, main pathogenesis and prevention and control strategies of primary liver cancer[J]. Chin J Oncol Prev Treat, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13.

    鲜林峰, 方乐天, 刘文斌, 等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13.
    [21] The Society of Liver Cancer, China Anti-Cancer Association. CACA guidelines for holistic integrative management of cancer-liver cancerpart[J/CD]. J Multidiscip Cancer Manag Electron Version, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.

    中国抗癌协会肝癌专业委员会. 中国肿瘤整合诊治指南(CACA)-肝癌部分[J/CD]. 肿瘤综合治疗电子杂志, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.
    [22] TIAN CX, ZHAO L. Epidemiological characteristics of colorectal cancer and colorectal liver metastasis[J]. Chin J Cancer Prev Treat, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12.

    田传鑫, 赵磊. 结直肠癌及结直肠癌肝转移流行病学特点[J]. 中华肿瘤防治杂志, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12.
    [23] WANG ZJ, KIM SY, TU W, et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment[J]. Cell Metab, 2023, 35( 7): 1209- 1226. e 13. DOI: 10.1016/j.cmet.2023.04.013.
    [24] XIAO JF, VARGHESE RS, ZHOU B, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J]. J Proteome Res, 2012, 11( 12): 5914- 5923. DOI: 10.1021/pr300673x.
    [25] ZENG HW, UMAR S, RUST B, et al. Secondary bile acids and short chain fatty acids in the colon: A focus on colonic microbiome, cell proliferation, inflammation, and cancer[J]. Int J Mol Sci, 2019, 20( 5): 1214. DOI: 10.3390/ijms20051214.
    [26] LI JY, GILLILLAND M 3rd, LEE AA, et al. Secondary bile acids mediate high-fat diet-induced upregulation of R-spondin 3 and intestinal epithelial proliferation[J]. JCI Insight, 2022, 7( 19): e148309. DOI: 10.1172/jci.insight.148309.
    [27] CHEN TL, XIE GX, WANG XY, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Mol Cell Proteomics, 2011, 10( 7): M110.004945. DOI: 10.1074/mcp.M110.004945.
    [28] COLLINS SL, STINE JG, BISANZ JE, et al. Bile acids and the gut microbiota: Metabolic interactions and impacts on disease[J]. Nat Rev Microbiol, 2023, 21( 4): 236- 247. DOI: 10.1038/s41579-022-00805-x.
    [29] ZHANG YF, LI MC. Application value of chitosanase 3-like protein 1, alpha-fetoprotein, glycoactrin 19-9, glutamyltranspeptidase in the early diagnosis of primary liver cancer[J]. Chin J Health Lab Technol, 2023, 33( 4): 467- 470.

    张艳芬, 李明才. 血清壳多糖酶3样蛋白1、甲胎蛋白、糖类抗原19-9及谷氨酰转肽酶在原发性肝癌早期诊断中的应用价值[J]. 中国卫生检验杂志, 2023, 33( 4): 467- 470.
    [30] YANG YP, XU EJ, WANG XX, et al. The value of GNB4 and Riplet gene methylation detection in the diagnosis of primary liver cancer[J]. Acta Univ Med Anhui, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028.

    杨玉萍, 徐恩君, 汪轩轩, 等. GNB4和Riplet基因甲基化检测在原发性肝癌诊断中的价值研究[J]. 安徽医科大学学报, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028.
    [31] ZHANG JL, SHEN Q, WANG N, et al. Values of serum 7 microRNAs alone or in combination with α-fetoprotein in diagnosing hepatocellular carcinoma[J]. Acad J Nav Med Univ, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648.

    张敬磊, 沈强, 王能, 等. 血清7种微RNA单独或联合甲胎蛋白检测对肝细胞癌的诊断价值[J]. 海军军医大学学报, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648.
  • 加载中
图(3) / 表(3)
计量
  • 文章访问数:  594
  • HTML全文浏览量:  148
  • PDF下载量:  39
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-01-24
  • 录用日期:  2024-04-15
  • 出版日期:  2024-10-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回